BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 32796071)

  • 21. Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.
    Henry Dunand CJ; Leon PE; Huang M; Choi A; Chromikova V; Ho IY; Tan GS; Cruz J; Hirsh A; Zheng NY; Mullarkey CE; Ennis FA; Terajima M; Treanor JJ; Topham DJ; Subbarao K; Palese P; Krammer F; Wilson PC
    Cell Host Microbe; 2016 Jun; 19(6):800-13. PubMed ID: 27281570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of a parainfluenza virus 5 (PIV5)-based H7N9 vaccine in mice and guinea pigs: antibody titer towards HA was not a good indicator for protection.
    Li Z; Gabbard JD; Johnson S; Dlugolenski D; Phan S; Tompkins SM; He B
    PLoS One; 2015; 10(3):e0120355. PubMed ID: 25803697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
    Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
    Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemagglutination Inhibition (HAI) antibody landscapes after vaccination with H7Nx virus like particles.
    Jang H; Ross TM
    PLoS One; 2021; 16(3):e0246613. PubMed ID: 33735274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.
    Tan GS; Leon PE; Albrecht RA; Margine I; Hirsh A; Bahl J; Krammer F
    PLoS Pathog; 2016 Apr; 12(4):e1005578. PubMed ID: 27081859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amino Acid Residue 217 in the Hemagglutinin Glycoprotein Is a Key Mediator of Avian Influenza H7N9 Virus Antigenicity.
    Chang P; Sealy JE; Sadeyen JR; Iqbal M
    J Virol; 2019 Jan; 93(1):. PubMed ID: 30282714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.
    Roubidoux EK; Carreño JM; McMahon M; Jiang K; van Bakel H; Wilson P; Krammer F
    mBio; 2021 Feb; 12(1):. PubMed ID: 33593972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-Linked Glycans and K147 Residue on Hemagglutinin Synergize To Elicit Broadly Reactive H1N1 Influenza Virus Antibodies.
    Huang Y; Owino SO; Crevar CJ; Carter DM; Ross TM
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
    Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
    Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development.
    Chen TH; Liu WC; Chen IC; Liu CC; Huang MH; Jan JT; Wu SC
    Vaccine; 2019 Nov; 37(47):6933-6941. PubMed ID: 31383491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of neutralizing antibodies to influenza A virus H7N9 by inactivated whole virus in mice and nonhuman primates.
    Pan W; Han L; Dong Z; Niu X; Li Z; Bao L; Li C; Luo Q; Yang Z; Li X; Huang J; Feng L; Qin C; Zhong N; Chen L
    Antiviral Res; 2014 Jul; 107():1-5. PubMed ID: 24746458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes.
    Lee AC; Zhu H; Zhang AJ; Li C; Wang P; Li C; Chen H; Hung IF; To KK; Yuen KY
    Clin Vaccine Immunol; 2015 Dec; 22(12):1235-43. PubMed ID: 26446420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.
    Zhang L; Jia N; Li J; Han Y; Cao W; Wang S; Huang Z; Lu S
    Hum Vaccin Immunother; 2014; 10(7):1949-58. PubMed ID: 25424804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans.
    Stadlbauer D; Rajabhathor A; Amanat F; Kaplan D; Masud A; Treanor JJ; Izikson R; Cox MM; Nachbagauer R; Krammer F
    mSphere; 2017; 2(6):. PubMed ID: 29242836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Escape Adaptive Mutations in the H7N9 Avian Influenza Hemagglutinin Protein Increase Virus Replication Fitness and Decrease Pandemic Potential.
    Chang P; Sealy JE; Sadeyen JR; Bhat S; Lukosaityte D; Sun Y; Iqbal M
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.
    Henry Dunand CJ; Leon PE; Kaur K; Tan GS; Zheng NY; Andrews S; Huang M; Qu X; Huang Y; Salgado-Ferrer M; Ho IY; Taylor W; Hai R; Wrammert J; Ahmed R; García-Sastre A; Palese P; Krammer F; Wilson PC
    J Clin Invest; 2015 Mar; 125(3):1255-68. PubMed ID: 25689254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
    Margine I; Krammer F; Hai R; Heaton NS; Tan GS; Andrews SA; Runstadler JA; Wilson PC; Albrecht RA; García-Sastre A; Palese P
    J Virol; 2013 Oct; 87(19):10435-46. PubMed ID: 23903831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.
    Meseda CA; Atukorale V; Soto J; Eichelberger MC; Gao J; Wang W; Weiss CD; Weir JP
    Sci Rep; 2018 Mar; 8(1):5364. PubMed ID: 29599502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.